Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders
Study Details
Study Description
Brief Summary
Evidence suggests that mGLUR5 availability may play a key role in the biology of mood disorders. This study aimed to investigate the changes in metabotropic glutamate receptor 5 (mGLUR5) availability and clinical symptoms in patients with MDD and bipolar disorder(BD) after two months of vortioxetine treatment. The investigators hypothesized that patients with MDD and BP have abnormal mGluR5 availability in certain brain regions, and baseline mGLUR5 availability can predict prognosis the prognosis of MDD and BD.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
MDD Participants with major depressive disorder (MDD), unmedicated and currently depressed to participate in MRI and [18F]FPEB PET scans |
Drug: Vortioxetine
All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.
|
Bipolar Participants with bipolar disorder, unmedicated and currently depressed to participate in MRI and [18F]FPEB PET scans |
Drug: Quetiapine
All patients with bipolar disorder will receive 50mg of Quetiapine at day 1, 100mg of Quetiapine at day 2, 200mg of Quetiapine at day 3, and 400mg of Quetiapine per day since day 4.
|
Healthy Control Healthy participant with no MDD or other psychiatric condition to participate in MRI and [18F]FPEB PET scans |
Outcome Measures
Primary Outcome Measures
- Baseline mGLUR5 availability [Day 0]
BPND at baseline as measured by PET
- Change in mGLUR5 availability from baseline to 8 weeks [Week 8]
BPND changes from baseline to 8 weeks
- Change of Hamilton Depression Rating Scale (HAMD) score from baseline to 8 weeks [Week 8]
Change of Hamilton Depression Rating Scale (HAMD) score from baseline to 8 weeks
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Meet DSM-V criteria for a current depressive episode.
-
Medication free for at least 4 weeks.
-
Score >21 on 24-item Hamilton Depression Rating Scale (HDRS), score >22 on Montgomery-Asberg Depression Rating Scale (MADRS), and score <6 on Young Mania Rating Scale (YMRS).
-
Age 18 to 60.
-
Able to give written informed consent.
Exclusion Criteria:
-
Have a current or past significant medical, neurological or metabolic disorder or head injury
-
Have active, significant suicidal ideation or past suicide attempts
-
Have implanted metallic devices or any MR contraindications
-
Are women who are pregnant or breastfeeding
-
Met DSM-5 criteria for substance use disorder
-
Met DSM-5 criteria for any current Axis I diagnosis (except Generalized Anxiety Disorder)
-
Are MDD patients present with delusions and/or hallucinations
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University | Changsha | Hunan | China | 410001 |
Sponsors and Collaborators
- Central South University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PCT 202007